RESUMEN
Objective To investigate the effects of inhibiting vesicular glutamate transporters (VGLUT) on pain behaviors in animals. Methods The latency in hot plate test, number of writhes in acetic acid and licking time in formeldehyde solution (formalin) tests were recorded to determine the analgesic effect of Chicago sky blue 6B (CSB6B), a selective VGLUT inhibitor. Results Intraperitoneal administration of CSB6B did not affect the acute thermal pain responses in hot plate test. In acetic acid writhing, compared with control group (26.50±2.97), CSB6B (2.5 mg/kg, ip) significantly attenuated the acetic acid-induced writhing (8.22±1.90) 30 min after administration (P<0.01); CSB6B (2.5 mg/kg, ip) significantly reduced the acetic acid-induced writhing (9.60±1.84) 60 min after administration (P<0.01). In Formalin test, compared with control group(139.40±21.02), CSB6B 0.5 mg/kg, ip) significantly reduced the licking time 75.10±19.45) 30 min after administration P<0.05) during the second phase, but not during the first phases. CSB6B(p) did not affect the licking time 2 h after administration during the first and second phases. Conclusion Inhibition of VGLUTs activity is sufficient to attenuate the inflammatory pain and this finding suggests that VGLUT participate in regulation of inflammatory pain and be a novel therapeutic strategy for treatment of pain.
RESUMEN
Objective To investigate the effects of inhibiting vesicular glutamate transporters (VGLUT) on pain behaviors in animals. Methods The latency in hot plate test, number of writhes in acetic acid and licking time in formeldehyde solution (formalin) tests were recorded to determine the analgesic effect of Chicago sky blue 6B (CSB6B), a selective VGLUT inhibitor. Results Intraperitoneal administration of CSB6B did not affect the acute thermal pain responses in hot plate test. In acetic acid writhing, compared with control group (26.50 ±2.97), CSB6B (2.5 mg/kg, ip) significantly attenuated the acetic acid-induced writhing (8.22±1.90) 30 min after administration (P<0.01);CSB6B (2.5 mg/kg, ip) significantly reduced the acetic acid-induced writhing(9.60±1.84) 60 min after administration(P<0.01). In Formalin test, compared with control group(139.40±21.02), CSB6B (0.5 mg/kg, ip) significantly reduced the licking time(75.10±19.45) 30 min after administration(P<0.05) during the second phase, but not during the first phases. CSB6B(ip) did not affect the licking time 2 h after administration during the first and second phases. Conclusion Inhibition of VGLUTs activity is sufficient to attenuate the inflammatory pain and this finding suggests that VGLUT participate in regulation of inflammatory pain and be a novel therapeutic strategy for treatment of pain.
RESUMEN
Vesicular glutamate transporters(VGLUTs)package specifically glutamate into synaptic vesicles in the presynaptic terminal for subsequent release into the synaptic cleft.VGLUT1 and VGLUT2 together label all glutamatergic neurons,are highly specific markers of glutamatergic neurons and their axon terminals.VGLUT1 and VGLUT2 are respectively the neurochemical marker of cortico-cortical projection and thalamo-cortical projection.VGLUT3 is also expressed in cholinergic interneurons,serotoninergic neurons,subsets of GABAergic interneurons in the hippocampus and cerebral cortex.The disfunction of VGLUTs can lead to the abnormal excitatory neurotransmitter glutamate,resulting in many nervous system disease.In order to give a clue for prevention and therapy of these diseases,this paper reviews the disfunction of VGLUTs effects on Alzheimer's disease(AD),Parkinson's disease(PD),schizophrenia,depressive disorder,epilepsy and deafness.